Business Context and Reporting Period
Company: Personalis, Inc. (PSNL)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter ended September 30, 2024
Business Overview: Personalis develops and markets advanced cancer genomic tests for precision oncology and provides sequencing services for population initiatives. The company operates as a single reportable segment. Key customers include pharmaceutical companies (e.g., Moderna), diagnostics companies (e.g., Natera), and government entities (e.g., VA MVP).
Key Financial Metrics
| Metric (in thousands) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Revenue | $25,709 | $18,247 | $67,814 | $53,806 |
| Cost of Revenue | $16,964 | $14,766 | $45,539 | $40,803 |
| Gross Profit | $8,745 | $3,481 | $22,275 | $13,003 |
| Gross Margin | 34.0% | 19.1% | 32.9% | 24.2% |
| Operating Loss | $(14,382) | $(30,793) | $(50,155) | $(85,964) |
| Net Loss | $(39,089) | $(29,098) | $(64,859) | $(81,712) |
| Diluted Net Loss Per Share | $(0.64) | $(0.60) | $(1.19) | $(1.71) |
| Cash and Cash Equivalents | $75,800 | $56,984 | $75,800 | $56,984 |
| Short-term Investments | $67,851 | $57,195 | $67,851 | $57,195 |
| Total Debt (Principal) | $1,645 | $2,904 | $1,645 | $2,904 |
| Working Capital | $133,864 | $99,510 | $133,864 | $99,510 |
Material Changes vs. Prior Period
- Revenue Growth: Q3 2024 revenue increased 41% year-over-year (YoY) to $25.7 million, driven primarily by a 96% increase in "Pharma tests and services" revenue ($15.7M vs. $8.0M). This was partially offset by a 33% decline in "Enterprise sales" ($5.3M vs. $7.8M) due to lower sample volumes and pricing adjustments with Natera.
- Expense Reduction: Total costs and expenses decreased 18% YoY in Q3 2024. Research and Development (R&D) expenses dropped 30% to $11.7M, and Selling, General, and Administrative (SG&A) expenses decreased 4% to $11.4M, reflecting the impact of workforce reductions implemented in 2023.
- Non-Cash Losses: The Net Loss for Q3 2024 was significantly impacted by a $26.1 million non-cash loss related to the remeasurement and settlement of warrants issued to Tempus AI, Inc. This item is classified under "Other income (expense), net."
- Liquidity Improvement: Cash and cash equivalents increased to $75.8 million from $57.0 million at year-end 2023, bolstered by financing activities.
Guidance, Outlook, and Risks
- Financing Activities: In Q3 2024, the company raised approximately $35.0 million from Tempus AI (warrant exercise and stock purchase) and $27.2 million via its At-The-Market (ATM) facility. Management believes current cash and investments are sufficient to fund operations for at least the next 12 months.
- Customer Concentration: Revenue remains highly concentrated. For the nine months ended September 30, 2024, Moderna (28%), Natera (31%), and the VA MVP (11%) accounted for the majority of revenue. The company expects its commercial relationship with Natera to wind down by the end of 2024 as Natera brings services in-house.
- Strategic Partnerships: The company continues to commercialize its NeXT Personal Dx test through its agreement with Tempus. It also received a new $7.5 million task order from the VA MVP in September 2024.
- Risks: Key risks include the potential loss of major customers (Natera, Moderna, VA MVP), reliance on sole suppliers (Illumina) for sequencing equipment, regulatory challenges regarding FDA enforcement of Laboratory Developed Tests (LDTs), and the need for additional capital if revenue growth does not offset operating expenses.
Investor Verification Checklist
- Tempus Warrant Impact: Verify the non-recurring nature of the $26.1 million non-cash loss in Q3 2024 and confirm that no further remeasurement losses are expected following the full exercise of warrants in August 2024.
- Natera Transition: Assess the timeline and financial impact of the expected wind-down of the Natera partnership by the end of 2024 and the company's strategy to replace this revenue stream.
- Pharma Revenue Sustainability: Confirm the duration of the revenue spike from the key personalized cancer therapy customer (Moderna), as management noted this revenue is expected to decline in upcoming quarters until new trials begin.
- Capital Runway: Review the burn rate relative to the $143.7 million in cash and short-term investments to validate the 12-month liquidity assertion.
- Regulatory Landscape: Monitor developments regarding the FDA's Final Rule on LDTs and its potential impact on the company's ability to market tests without premarket approval.